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David S Gibson1,5* and Madeleine E Rooney1,4
Abstract
Introduction: Juvenile idiopathic arthritis (JIA) is the most common rheumatological disease of childhood with a
prevalence of around 1 in 1,000. Without appropriate treatment it can have devastating consequences including
permanent disability from joint destruction and growth deformities. Disease aetiology remains unknown.
Investigation of disease pathology at the level of the synovial membrane is required if we want to begin to
understand the disease at the molecular and biochemical level. The synovial membrane proteome from early
disease-stage, treatment naive JIA patients was compared between polyarticular and oligoarticular subgroups.
Methods: Protein was extracted from 15 newly diagnosed, treatment naive JIA synovial membrane biopsies and
separated by two dimensional fluorescent difference in-gel electrophoresis. Proteins displaying a two-fold or greater
change in expression levels between the two subgroups were identified by matrix assisted laser desorption ionization-
time of flight mass spectrometry with expression further verified by Western blotting and immunohistochemistry.
Results: Analysis of variance analysis (P ≤ 0.05) revealed 25 protein spots with a two-fold or greater difference in
expression levels between polyarticular and oligoarticular patients. Hierarchical cluster analysis with Pearson ranked
correlation revealed two distinctive clusters of proteins. Some of the proteins that were differentially expressed
included: integrin alpha 2b (P = 0.04); fibrinogen D fragment (P = 0.005); collagen type VI (P = 0.03); fibrinogen
gamma chain (P = 0.05) and peroxiredoxin 2 (P = 0.02). The identified proteins are involved in a number of different
processes including platelet activation and the coagulation system.
Conclusions: The data indicate distinct synovial membrane proteome profiles between JIA subgroups at an early
stage in the disease process. The identified proteins also provide insight into differentially perturbed pathways
which could influence pathological events at the joint level.
Introduction
Juvenile idiopathic arthritis (JIA) consists of a heteroge-
neous group of diseases which persist for more than six
weeks and commence before the age of 16. It is the most
common rheumatological disease of childhood, with a
prevalence of approximately 1/1,000 [1]. The cause of
JIA remains unknown; however, environmental and gen-
etic factors play a role in its pathogenesis and the
heterogeneity of the disease would suggest multiple fac-
tors are responsible [2]. Adverse outcomes include
chronic pain and stiffness, and joint damage and dis-
ability as a result of chronic joint inflammation. Despite
improved prognoses for JIA patients in recent years,
around half of patients will continue to have active joint
disease into adulthood [3].
The International League of Associations for Rheuma-
tology (ILAR) classification system divides JIA into seven
clinical subgroups [4,5]. The largest subgroup - oligoarti-
cular JIA - accounts for approximately 65% of all cases
and refers to children with four or fewer joints involved
within six months of diagnosis. Oligoarticular disease is
further defined as persistent when it remains confined to
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four or fewer joints throughout the course of the disease.
Oligoarticular JIA is more prevalent in females, with a
peak age of onset of one to three years [6]. Polyarticular
JIA is defined by the involvement of more than four joints
within six months of diagnosis, it accounts for around 10
to 15% of all JIA cases [7].
Very few studies examine the synovial membrane from
JIA patients and, of those available, most involved pa-
tients with established disease and on disease modifying
treatment [8-11]. Our previous immunohistochemical
study demonstrated significant differences in the inflam-
matory infiltrates and levels of vascularisation in the dif-
ferent JIA subgroups. It is still unclear, however, why
these changes take place in JIA and why they differ
between subgroups. Proteomics offers an unsupervised
means to investigate the disease process within the
affected tissue.
This study was designed to investigate how the predom-
inant protein expression profile within synovial membrane
varies between persistent oligoarticular and polyarticular
JIA across a group of newly diagnosed, treatment-naïve
patients. We hypothesize that subtype-specific protein
expression patterns exist in the early stages of disease.
Comparison of the synovial proteome between polyarticu-
lar and oligoarticular JIA patients could provide a much
needed insight into the pathology underlying these two
distinct subtypes.
Materials and methods
Patients
Children with newly diagnosed JIA of less than two years
duration were consecutively recruited following informed
consent. Medical Ethics Committee approval was obtained
for this study at Green Park Healthcare Trust and patient
assent and parent informed consent was given (ORECNI
408/03). Recruitment criteria included: involvement of
one knee joint that required intra-articular steroid injec-
tion, and the patient being steroid and disease-modifying
antirheumatic drug (DMARD) naive. Children were classi-
fied according to the ILAR criteria at the time of recruit-
ment. Children were then reclassified after two years of
follow-up. Detailed clinical examination, biochemical and
immunological data, and imaging assessments were ob-
tained. Subgroups were compared with each other as it
was not ethically possible to obtain synovial membrane
biopsies from healthy paediatric controls.
Tissue collection
Synovial membrane samples were obtained by blind
needle biopsy using ultrasound guidance as described pre-
viously [12]. Biopsies were obtained prior to the instilla-
tion of steroids. Tissue was wrapped in saline soaked
gauze, immersed in saline and placed in sterile containers
on ice. Biopsies were snap frozen in liquid nitrogen and
stored at −80°C.
Sample preparation
Protein was extracted from synovial membrane biopsies
in lysis buffer (8.4 M urea, 2.4 M thiourea, 4% 3-[(3-chola-
midopropyl)dimethylammonio]-1-propanesulfonate, 2 mM
dithiothreitol (DTT), 1% ampholytes). Samples were centri-
fuged at 12,000 rpm for 15 minutes and the supernatant
collected. Protein was precipitated in ice cold acetone
at −20°C overnight, pelleted by centrifugation and the pellet
air dried to remove residual acetone. The protein pellet was
resuspended in difference in-gel electrophoresis (DIGE)
lysis buffer (30 mM Tris-Cl, 7 M urea, 2 M thiourea, 4%
CHAPS, pH 8.5) and protein concentration was determined
using a modified Bradford assay.
Difference in-gel electrophoresis (DIGE)
DIGE was performed as previously described [13] with the
exception that isoelectric focusing (IEF) and 2D PAGE
were performed on 11 cm Immobiline DryStrip pH 4 to 7
linear. Each gel contained one synovium sample from a
polyarticular patient and one synovium sample from an
oligoarticular patient (each labelled with either Cy3 or
Cy5 dyes). Cy3 and Cy5 dyes were swapped randomly bet-
ween samples to prevent dye bias. Each gel also contained
the internal standard which is a pooled mixture of every
patient sample (labelled with Cy2). Voltage and times
were adjusted accordingly. Two preparative gels loaded
with 300 μg of protein were Coomassie stained and spots
excised for identification by mass spectrometry.
Image analysis
DIGE gels were scanned using a Typhoon 9410 imager (GE
Healthcare, Bucks, UK). Gel images were analysed using
Progenesis Samespots software version 2.0 build 2644.18003
(Nonlinear Dynamics Ltd., Newcastle upon Tyne, UK) as
previously described [14]. PermutMatrix [15] was subse-
quently used to cluster and visualise the spot data as previ-
ously described [14].
Tryptic digestion of protein spots and MALDI target
spotting
Tryptic digestion of protein bands was performed using a
ProGest robot (Genomic Solutions, Holliston, MA, USA)
programmed with the long trypsin digestion method. A
sterile pipette tip, cut to increase the bore width (approxi-
mately 2.0 mm), was used for spot excision. Gel plugs
were then transferred to a 96-well plate. This plate is de-
signed with microscopic holes at the bottom of the wells
which allows for positive displacement of liquids during
reagent changes on the robot. Gel pieces were first equili-
brated in 50 μl of 50 mM ammonium bicarbonate and
proteins were reductively alkylated with 10 mM DTT and
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100 mM iodacetamide followed by de-staining of the pro-
tein bands and desiccation of the gel plugs with aceto-
nitrile. Gel plugs were rehydrated with 50 mM
ammonium bicarbonate containing 5% trypsin and the
proteins were digested for 12 hours at 37°C. Resulting
peptides were extracted from the gel plugs with 2 × 25 μl
washes of 50% acetonitrile, 0.1% TFA. Peptide extracts
were freeze dried and then re-suspended in 10 μl of 0.1%
formic acid. A saturated solution of α-cyano-4-hydroxy-
cinnamic acid was prepared in 50% acetonitrile, 0.1%TFA,
10 mM ammonium acetate. For each sample, 1 μl of
matrix solution was spotted on the matrix assisted laser
desorption ionisation (MALDI) target immediately
followed by 1 μl of sample into the matrix spot and the
sample/matrix droplet allowed to slowly air dry.
MALDI TOF-TOF analyses, database searching and protein
identification
Matrix assisted laser desorption ionisation-tandem time of
flight (MALDI TOF-TOF) analyses was performed on a
4800 mass spectrometer (AB Sciex UK Limited, Cheshire,
UK) using the following protocol: TOF-MS analyses was
first performed on all of the dried target spots using
automated data acquisition and processing under the
control of Applied Biosystems 4000 series Explorer
software (version 3.5) using reflector mode, a mass
range of 700 to 4,000 m/z, 1,000 total laser shots per
spectrum and a laser intensity of 3,300 V. Following ac-
quisition the TOF-MS spectra were noise corrected,
peak de-isotoped and internally calibrated using the
trypsin autolysis peaks 842.500 and 2,211.100 m/z. The
eight most abundant precursor ions from each spectra
were then selected by the software for fragmentation
and MS-MS analyses using a 1 kV collision ion dissoci-
ation (CID) fragmentation method collecting 4,000
laser shots per spectra with a laser intensity of 3,800
over the mass range.
Peak lists of ion masses were generated by GPS Ex-
plorer software version 3.6 (Applied Biosystems) from
the calibrated and de-isotoped MS and MS-MS spectra
for each sample. Combined lists of MS and MS-MS data
were used for database searching with MASCOT ver-
sion 2.2 (Matrix Science), against all entries in the Na-
tional Center for Biotechnology Information (NCBI)
database. Database search parameters used were the fol-
lowing: digestion enzyme trypsin, single missed cleavage
allowed, variable modifications of carboxymethyl cyst-
eine and oxidised methionine, precursor mass tolerance
of 50 ppm and fragment ion tolerance of 0.2 Da. HTML
pages of MASCOT output were generated for each
sample.
The Mowse scoring algorithm was used to determine
the significance of the identity. Additional criteria were
used to ensure correct protein identifications. These
included ensuring the matched peptides were the most
abundant peaks in the mass spectrum, the theoretical
isoelectric point and molecular weight of the identified
protein correlated with the spot’s position on the 2D gel,
and sequence coverage was high.
Immunohistochemistry
Biopsies were snap frozen in liquid nitrogen for section-
ing and stored at −80°C. A total of 7 μm thick frozen
sections were cut using a Leica CM 1900 cryostat
(Leica Microsystems Nussloch GmbH, Germany) and
allowed to air-dry at room temperature for 30 minutes.
Primary antibodies used were monoclonal anti-integrin
alpha 2b antibody (ITA2B) (Abcam, Cambridge, UK),
monoclonal anti-peroxiredoxin 2 (PRDX2) (Sigma, Dorset,
UK) and polyclonal anti-myosin regulatory light chain 2
(MYL2) (Sigma, Dorset, UK). Immunostaining was per-
formed using a standard protocol and staining was visual-
ized using the diaminobenzidine (DAB) method [16].
Sections were counterstained with haematoxylin.
Western blotting
Western immunoblot analysis was performed using a
standard protocol using the above antibodies against
ITA2B, PRDX2 and MYL2.
Results
Patient demographics and clinical features
There were 12 females and 3 males included in the
study. The clinical and laboratory data of patients are
shown in Table 1.
General laboratory characteristics of JIA patients
There was no significant difference in the age at disease
onset between the two groups. VAS pain scores (parent)
were significantly higher in the polyarticular as were
ESR and CRP levels (Table 1).
2D DIGE analysis
We compared the synovial membrane proteome from
seven persistent oligoarticular JIA patients with eight poly-
articular JIA patients using 2D DIGE. 2D DIGE analysis
revealed an average of 460 spots per pH 4 to 7, 11 cm gel
which were matched across all gels (Figure 1). ANOVA re-
vealed 26 spots that were differentially expressed (two-fold
or more change in expression levels) between polyarticu-
lar and oligoarticular patients (P ≤0.05).
Hierarchical cluster analysis (HCA)
HCA was used to examine the expression patterns of
the 26 differentially expressed proteins across the study
cohort with results depicted in heat map form (Figure 2).
Depicted on the horizontal axis is the patient num-
ber and on the vertical axis is the spot number/
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Table 1 Demographic and clinical characteristics at the time of biopsy
ILAR subtype JIA patient
study ID
M/F Disease
duration
(months)
No. of
swollen
joints
VAS*
pain
(parent)
VAS*
global physician
WCC* Hb* ESR* CRP*
(mg/l)
PC* ANA* RF
(+/−)
Oligoarticular (n = 7) 1 F 4 1 5 1.9 7.5 11 8 0 407 0 -
2 M 4 1 0 0.8 12 11 11 0 415 0 -
3 F 6 3 3.6 2.9 12.1 11 10 5.7 453 0 -
4 F 10 2 0.3 1.9 6.9 10.7 4 4 315 0 -
5 F 5 3 7.5 3 12.8 10.6 37 26 407 80 -
6 M 20 1 1.4 1.9 5.6 14.1 5 0 249 0 -
7 F 4 3 4.3 1.8 9.1 8.9 62 66.5 460 0 -
Mean values 7.6 2 3.2 2 9.4 11 19.6 14.6 386.6 11.4
Polyarticular (n = 8) 8 F 2 24 8.7 7.5 12.9 8.3 38 27.5 570 160 -
9 F 2 9 8.3 3.3 13.9 10.4 22 36.1 232 0 -
10 F 2 24 4.7 5.7 12.2 10.5 30 67.3 601 0 -
11 F 2 6 9 4.8 9.9 11.1 26 32.1 446 80 -
12 F 1 2 7.1 1.5 11.2 10.4 96 47.4 522 ND -
13 F 4 15 9.8 3.6 11.8 7.2 110 72 578 0 -
14 M 10 4 3.3 5.3 10.27 11 20 5.4 314 40 +
15 F 5 25 6.5 7.4 9.3 8.4 138 181 401 80 +
Mean values 3.5 13.6 7.2 4.9 11.4 9.7 60 58.6 458 51.4
t-test p value ns ns 0.004 0.002 0.056 0.049 0.029 0.03 0.12 - -
ANA, anti-nuclear antibodies; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; Hb, haemoglobin; ns, not statistically significant at P ≥0.05; PC, platelet
count;; RF, rheumatoid factor; *VAS, visual analogue scale; WCC, white cell count.
Figure 1 A representative 2D DIGE gel image of JIA synovial membrane proteins. Proteins labeled using fluorescent dyes Cy3 (green) and
Cy5 (red). Protein samples were separated on an 11 cm pH4 to 7 IPG strip and on a 12.5% homogenous SDS-PAGE gel. Protein spots analysed by
mass spectrometry are highlighted by spot outlines. Spot numbers correspond with those listed in Table 2, Additional file 1: Table S1 and Figure 2.
Proteins overexpressed in oligoarticular patients are indicated by red spot outlines; proteins overexpressed in polyarticular are indicated by blue
spot outlines. DIGE, difference in-gel electrophoresis; JIA, juvenile idiopathic arthritis.
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protein ID. Pearson ranked correlation revealed two distinct
clusters of proteins. Cluster 1 contains proteins that were
overexpressed in the polyarticular patients, whereas pro-
teins in cluster 2 are overexpressed in the oligoarticular
subgroup. It seemed conceivable that these two distinct
clusters could be used in combination to differentiate these
two disease subgroups.
MALDI-TOF MS protein identification
Differentially expressed proteins were identified by
MALDI MS (Table 2). Peptide ion validation data is avail-
able as an additional file (Additional file 1: Table S1). Pro-
teins that were overexpressed in the polyarticular group
included: chain A of profilin-beta-actin (P = 0.04); alpha-1
subunit of F-actin capping protein (P = 0.03); beta actin,
(P = 0.04); beta actin (P = 0.02); myosin regulatory light
chain 2 (MYL2) isoform B (P = 0.02); myosin regulatory
light chain 9 (MYL9), isoform a (P = 0.04); beta actin
variant (P = 0.005); peroxiredoxin 2 (PRDX2), isoform a
(P = 0.02); mixture of protein kinase C inhibitor protein 1
(KCIP-1) and annexin A5 (P = 0.003); fibrinogen gamma
chain (P = 0.004 and P = 0.05).
Proteins overexpressed in the oligoarticular group
included: collagen type VI, alpha 2 (P = 0.03); integrin alpha
2b (ITA2B) (P= 0.04); chain C of fibrinogen fragment D
(P= 0.005); Chain C, crystal structure of fibrinogen fragment
D (P= 0.0002). Figure 3 shows representative differentially
expressed proteins along with a 3D image of the relative
quantities of proteins generated using Samespots software
(Nonlinear Dynamics Ltd., Newcastle upon Tyne, UK).
The levels of proteins 27 to 31 (listed in Table 2) did not
differ between oligoarticular and polyarticular patient
groups. There were a number of proteins that could not
be identified due to their low abundance in the gel.
Confirmation of protein localisation and expression
Figure 4 shows representative images of MYL2, PRDX2
and ITA2B immunostaining in polyarticular and oligoar-
ticular synovial membrane: (A) MYL2 staining is limited
to a small number of discrete cells within the sublining
layer in the oligoarticular tissue (arrows), its expression in
the polyarticular tissue (B) is more intense. PRDX2 stain-
ing is sparse in the oligoarticular tissue (arrows) (C) with
more intense staining in the polyarticular tissue (D).
ITA2B staining is localised to blood vessels in oligoarticu-
lar tissue (E), some ITA2B staining was also observed in
the polyarticular tissue (F) around blood vessels (arrows).
Figure 5 depicts the synovial membrane expression levels
for the aforementioned proteins across a representative
subset of the study patients.
Discussion
This is the first study to identify synovial membrane pro-
tein expression patterns that discriminate clinical sub-
groups in early treatment of naive JIA. By understanding
the early pathological changes taking place at the disease
Figure 2 Hierarchical cluster analysis of proteins expressed with statistically significant differences between patient subgroups. The
inter-individual and inter-group variation in 19 selected proteins is represented in the form of a heatmap. The protein expression data were reordered by
hierarchical cluster analysis (HCA) using Pearson centred correlation (unweighted pair group method with arithmetic mean (UPGMA)), which revealed
specific expression patterns. Two main clusters of proteins are highlighted by the coloured bars (blue, red). Each patient sample is represented by a single
numbered column (oligarticular 1 to 7 and polyarticular 9 to 15). Spot numbers and protein identifications (UniProt code) are labelled on the vertical axis;
unidentified protein spots are indicated by an asterix (*). The relative amount of a protein is denoted by colour intensity within a spectrum of black to
red, red being the highest amount.
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Table 2 Mass spectrometry and DIGE quantification data of synovial membrane proteins
Spot
number
Protein Gene
symbol
Accession # Mowse
score
% Sequence
coverage
CalculatedpI
value
Nominal
mass (Mr)
Number matched
peptides
Normalised
volume (Oligo)
Normalised
volume (Poly)
ANOVA
P-value
1 No ID - - - - - - - 0.73 3.02 0.001
2 Protein kinase C inhibitor protein 1 KCIP-1 gi|114629705 88 40 4.78 24,166 14 1.07 2.1 0.03
Annexin A5 ANXA5 gi|149698420 79 33 4.98 35,977 10 - - -
3 Myosin regulatory l ight chain 9 MYL9 gi|29568111 52 29 4.8 19,814 8 0.92 2.02 0.04
4 No ID - - - - - - - 0.79 2.35 0.006
5 Beta Actin ACTB gi|15277503 76 21 5.55 40,194 9 1.14 2.28 0.04
6 Beta Actin ACTB gi|15277503 176 37 5.55 40,194 17 0.35 1.24 0.02
7 Fibrinogen gamma chain FGG gi|930064 94 50 6.49 24,109 11 0.88 2.23 0.004
8 Beta actin variant ACTB gi|62897625 451 53 5.37 41,738 23 0.56 1.94 0.005
9 No ID - - - - - - - 0.64 2.04 0.02
10 Chain A, profi l in-beta-actin PFN1 gi|157111829 106/130 44 5.29 41,616 21 0.39 1.76 0.04
11 F-actin capping protein alpha-1 CAPZA1 gi|5453597 196 55 5.45 32,902 17 0.3 1.38 0.03
12 Myosin regulatory l ight chain 2 MYL2 gi|222144328 86 55 4.26 17,745 10 0.66 2.03 0.02
13 No ID - - - - - - - 0.62 1.72 0.05
14 Peroxiredoxin 2 PRDX2 gi|4758638 348 57 6 25,019 18 0.3 1.73 0.02
15 Chain C, fibrinogen fragment D FFD gi|2781209 89 42 5.87 36,157 12 2.08 0.58 0.0002
16 Fibrinogen gamma chain FGG gi|930064 71 44 6.49 24,109 7 0.9 2.14 0.05
17 Collagen, type VI, alpha 2 COL6A2 gi|41350923 81 18 5.85 182,860 18 2.77 1.09 0.03
18 Chain C, fibrinogen fragment D FFD gi|24987625 102 44 5.86 35,155 14 2.1 0.96 0.005
19 No ID - - - - - - - 1.6 0.9 0.008
20 No ID - - - - - - - 1.6 0.8 0.02
21 No ID - - - - - - - 1.4 0.7 0.006
22 No ID - - - - - - -
23 Integrin, alpha 2b ITGA2B gi|119571979 95 15 5.41 103,127 16 1.87 0.64 0.04
24 Alpha 3 type VI collagen COL6A3 gi|62088852 119 17 8.73 182,860 27 1.78 0.78 0.05
25 No ID - - - - - - - 1.72 0.74 0.04
26 No ID - - - - - - - 1.56 0.72 0.02
27 Peroxiredoxin 6 PRDX6 gi|4758638 348 57 6 25,019 18 - - -
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Table 2 Mass spectrometry and DIGE quantification data of synovial membrane proteins (Continued)
28 Triosephosphate isomerase 1 TPI1 gi|17389815 111 53 6.45 26,625 15 - - -
29 Albumin, isoform CRA_j ALB gi|119626073 59 23 6.4 26,233 7 - - -
30 Calreticul in precursor variant CRT gi|62897681 236 29 4.3 46,890 19 - - -
31 Fibrinogen, beta chain FGB gi|70906435 93 34 8.54 55,892 21 - - -
Spot trypsin digests were identified using matrix assisted laser desorption ionization (MALDI-TOF/TOF), correlated to compiled peptide data (Matrix Science). P-values highlight inter-subgroup comparisons which
reached statistical significance (P <0.05) by ANOVA. Full mass spectra peak lists for each identified protein are provided in Additional file 1: Table S1.
Finnegan
et
al.A
rthritis
Research
&
Therapy
2014,16:R8
Page
7
of
12
http://arthritis-research.com
/content/16/1/R8
Figure 3 DIGE image analysis of differentially expressed synovial membrane proteins. Spots 22, 23 (integrin alpha 2b) and 24 (collagen)
were overexpressed in the oligoarticular group. Spots 14 (peroxiredoxin 2) and 16 (fibrinogen gamma chain) were overexpressed in the
polyarticular group. JIA, juvenile idiopathic arthritis.
Figure 4 Immunohistochemical staining of differentially expressed synovial membrane proteins. A and B Distribution of myosin
regulatory light chain 2 (MYL2), C and D peroxiredoxin 2 (PRDX2), E and F integrin alpha 2b (ITA2B) in oligoarticular and polyarticular synovial
membrane. Sections were counterstained with haematoxylin. Arrows indicate areas of positive staining.
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site we can begin to elucidate the disease process. There
have been a number of proteomic investigations of syn-
ovial tissue in adult inflammatory disease [17-19] but not
in children. To date, proteomic studies of JIA have
focused on synovial fluid and plasma [13,14,20-22], due to
the fact that synovial membrane is extremely difficult to
acquire. The synovial membrane has an advantage over
synovial fluid in that it is the actual site of pathology in
JIA. It is also important to note that all synovial mem-
branes used in this study were from treatment-naive early
disease-stage patients (average disease duration at time of
biopsy was 5.4 months). For the purpose of this study the
differences in two JIA subgroups were noted. Although
control tissue from healthy subjects would have been use-
ful, such tissue is not obtainable for ethical reasons.
A number of proteins identified in this study were part of
a ‘charge train’ on the 2D gels, indicating post translational
modification (PTM). A recently published study by our
group indicates that protein modification acts as a surrogate
marker of inflammation spread in JIA [23]. Glycosylation of
VDBP- Vitamin D-binding protein, which confers macro-
phage activation activity, was decreased in patients at risk
of disease spread. Subtype-specific protein isoforms uncov-
ered within the current study should also be carefully inves-
tigated for post translational modifications. In early disease
discrete protein isoforms may play a role in the different
pathologies observed between oligoarticular and polyarticu-
lar synovium. In an earlier study we reported histological
features which distinguish these JIA subgroups, including
levels of vascularisation and white blood cell infiltration
[16]. The likely pathological impact of synovial protein iso-
forms identified in the current study are subsequently dis-
cussed, along with their potential as therapeutic targets.
ITA2B was overexpressed in the oligoarticular group
as part of a ‘charge train’ of spots (Figure 3), strongly
suggesting a process of serial post translational modifica-
tions. ITA2B contains five N-linked glycosylation points
[24]. Furthermore, intense ITA2B immunostaining was
observed around blood vessels in the oligoarticular
group, relative to polyarticular tissue. ITA2B is a major
integrin found on platelet plasma membranes, assisting
platelet activation and adhesion and thrombus formation
at sites of vascular injury [25]. A previous study reported
similar ITA2B expression patterns in rheumatoid arth-
ritis (RA) synovial membrane, restricted to vascular
endothelial cells [26]. ITA2B could act as a key target in
controlling inflammation, as platelets can elicit cytokine
responses from synovial fibroblasts via interleukin-1 in
RA patients. The apparent increase in ITA2B observed
in oligoarticular patients may result from leaky and tor-
tuous vessels observed in the development of synovitis.
Fibrinogen fragment D was also expressed at higher
levels in the oligoarticular group as part of a ‘charge
train’. The D-dimer of fibrin is a degradation product
(FDP) found in the blood following fibrinolysis of a
blood clot [27]. Under various inflammatory conditions,
including RA, fibrin degradation product levels are
increased [28,29], suggesting an imbalance in the coa-
gulation/fibrinolysis system. D-dimers have also been
shown to trigger release of IL-1β, IL-6 in peripheral
blood monocytes [30]. Fibrinogen is one of several pro-
tein targets for citrullination in RA [31] and citrul-
linated fibrinogen D fragments have been detected in
synovial exosomes from patients with RA and osteo-
arthritis (OA).
In contrast, fibrinogen beta and gamma chains were
overexpressed in the polyarticular group. Fibrinogen
gamma chains are involved in fibrin polymerization and
cross-linking, interacting with platelets and mediating
thrombin binding to fibrin [32]. Rosenkranz et al. also
Figure 5 Validation of protein expression changes by Western immunoblot probing for MYL2, PRDX2 and ITA2B. Each lane represents
an individual patient synovial membrane protein sample. β-actin was used as a loading control. ITA2B, integrin alpha 2b; MYL2, myosin regulatory
light chain 2; PRDX2, peroxiredoxin 2.
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observed that fibrinogen gamma chain levels were in-
creased in systemic JIA synovial fluid relative to oligoarti-
cular patients [21]. Fibrinogen beta chain is also increased
in patients with recurrent joint inflammation [22]. A re-
cent study also demonstrated strong reactivity of JIA sera
to anti-citrullinated fibrinogen antibodies [33]. Fibrinogen
has been shown to be the target of citrullination not only
in JIA but also in adult RA [34], suggesting it may have an
important role to play in autoimmunity.
During a normal inflammatory response, activation of
coagulation and deposition of fibrin are crucial events
that help regulate and contain inflammatory activity to
the site of injury or infection. It is, therefore, possible
that altered levels of coagulation system proteins re-
ported in polyarticular tissue may indirectly assist in the
spread of inflammation to multiple joints, a key charac-
teristic of these patients. It would be intriguing to target
these fragments in an animal model of arthritis to deter-
mine their function in the synovium.
The collagens are a superfamily of extracellular matrix
proteins that play a crucial role in maintaining tissue in-
tegrity. Type VI collagen is a prominent constituent of the
synovial extracellular matrix [35]. A study by Alexopoulos
et al. suggests that type VI collagen has an important role
in the regulation of normal synovial joint physiology and
pericellular matrix displayed significantly reduced me-
chanical properties in mice lacking type IV collagen. Thus,
as the mice aged, accelerated development of joint de-
generation, as well as a number of other musculoskeletal
abnormalities, was noted [36]. Collagen type VI was found
at higher levels in the oligoarticular subgroup. Disease
pathology is much less severe in this group, and it is pos-
sible that this is due to increased tissue integrity and a
more stable extracellular and pericellular matrix in the
synovial membrane.
A number of actin family proteins were overexpressed
in the polyarticular group. Citrullinated F-actin capping
protein alpha-1 subunit autoantigens have been identified
in RA synovium [19]. It is thought that one of the patho-
genic mechanisms taking place in RA is the promotion of
actin polymerization and rearrangement of the actin cyto-
skeleton. Indeed, a previous study found a number of
deregulated genes in synovial fibroblasts known to be in-
volved in actin filament and cytoskeleton organisation
[37]. Reorganisation of the actin cytoskeleton and the as-
sociated deregulation of ECM adhesion are known to be
an intrinsic property of arthritic synovial fibroblasts. The
presence of higher levels of these cytoskeletal proteins in
the polyarticular group could reflect the severe disease
pathology in this group and is consistent with much
higher levels of synovial hyperplasia and cytoskeletal
reorganisation.
PRDX2 was found at higher levels in the polyarticular
group. Peroxiredoxin is involved in redox regulation.
Peroxiredoxins constitute a ubiquitous family of antioxi-
dant enzymes that are involved in the control of cytokine-
induced peroxide levels [38]. Lymphocytes from RA pa-
tients have been shown to have increased levels of intra-
cellular PRDX2 when compared to healthy controls [39].
Autoantibodies against peroxiredoxin have also been iden-
tified in RA [40]. Increased levels of PRDX2 in the pol-
yarticular patients may indicate a dysregulated redox
response system similar to that observed in adult RA.
Conclusions
There are still substantial gaps in our understanding of
JIA disease pathogenesis. As a result, JIA specific treat-
ments have lagged behind the management of other
adult arthritides. Identifying pathology specific proteins
with functions in key cellular processes may provide
help to prioritize putative therapeutic targets. We hy-
pothesize that an imbalance in clotting factors, which
primarily control plasma cell activation and thrombus
formation, is associated with the involvement of multiple
synovial joints in early stage JIA. In the case of polyarti-
cular patients, diminished levels of specific clotting fac-
tors may prevent the repair of leaky neovasculature and
increase the chances that multiple joints will be affected.
Further targeted investigations of the circulating levels
of the aforementioned factors in a suitably powered in-
dependent study cohort are required to robustly test this
theory. Murine knockout models of arthritis which can
sequentially test the function of the identified members
of clotting pathways could also be used to verify this
hypothesis.
Alternately, if the integrin alpha 2b is expressed exclu-
sively on pathogenic vasculature, this property could be
exploited to specifically target poorly formed vessels with
integrin recognition (RGD) peptides. Integrin homing-
RGD peptides have been shown to preferentially target in-
flamed synovium vessels without damaging other synovial
tissues [41]. These small proteins could be linked to thera-
peutic agents, or clotting agents to clog the vessels which
fuel the ensuing synovitis.
In summary, proteomic analysis of synovial tissue from
early disease-stage JIA patients has revealed novel patho-
logical protein expression patterns. With further work,
molecular pathways which discriminate JIA subtypes
could be exploited to develop new treatment strategies
which suppress disease and reduce the risk of long term
joint damage.
Additional file
Additional file 1: Table S1. Peptide ion validation data from collision
ion dissociation (CID) MS/MS mass spectrometry which correspond with
Table 2. Peptide position in the matched protein, observed mass (m/z)
and amino acid sequence are listed for each protein match found.
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